SAT0329 IMPACT OF AXIAL SPONDYOARTHRITIS (AXSPA) ON SOCIAL AND FAMILY LIFE: RESULTS OF THE EMAS SURVEY OF 638 PATIENTS IN 2018
Authors: Laure Gossec, Pascal Claudepierre, René-Marc Flipo, Marco Garrido-Cumbrera, Emilie Desfleurs, Francoise Alliot Launois, Laurent Grange
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Axial Spondyloarthritis (axSpA) has an impact on daily life, but data in the biologics era are scarce. <h3>Objectives</h3> To assess the patient-reported impact of axSpA on social and family life. <h3>Methods</h3> Between December 2017 and February 2018, patients followed for axSpA by their rheumatologists or affiliated to the French patients association AFLAR, and self-reporting axSpA, participated in the European Map of Axial Spondyloarthritis (EMAS) cross-sectional patient survey in France1. Socio-demographics and disease characteristics were collected and the impact of axSpA on personal life was evaluated through a questionnaire established by an international committee on social interactions (better/worse), frequency of social activities (less or more frequent), patient fears and the impact of flares on 10 aspects of daily life evaluated as no/low to moderate/severe. No imputation of missing data was performed and the analyses were descriptive. <h3>Results</h3> Data from 638 persons, mean age 41.5±11.1 years, 77% women, mean disease duration 6.9±8.2 years, 19.1% on biologics, were analyzed. The disease (axSpA) was often active (mean BASDAI: 5.9±1.7). Social interactions were reported as worse or much worse since axSpA: with friends (43%), work colleagues (39%), spouse (35%) and family (31%). AxSpA had also an impact on the frequency of social and sport activities, which were «much less frequent than before» for sport (52%), travels (38%), sexual intercourse (31%) and cultural outings (29%). A moderate to severe impact of disease flares was reported on walking in the street (53%), intimate relations (49%) and personal hygiene (35%). Regarding fears linked to the disease, 71% of participants feared being unable to do their daily tasks and loosing autonomy and 42% feared social isolation. <h3>Conclusion</h3> More than half of patients with axSpA in France described a negative impact of axSpA on their family and social life, in a context of fears for the future. These data are important to take into account for shared decision-making. <h3>Reference</h3> [1] Gossec L, et al. Diagnostic Delay and Associated Factors in Axial Spondyloarthritis across Europe. Results from the European Map of Axial Spondyloarthritis Survey. Arthritis Rheumatol.2018Sep;70Suppl 9:688 <h3>Acknowledgement</h3> Survey supported by Novartis <h3>Disclosure of Interests</h3> Laure Gossec Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Sanofi, and UCB, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Novartis-Sandoz, Pfizer, Roche, Sanofi, and UCB, Consultant for: L Gossec has received honoraria from Celgene as investigator for this study, Pascal Claudepierre Consultant for: Honoraria from Novartis as steering committe of this survey, René-Marc Flipo Consultant for: Honoraria from Novartis as steering committe of this survey, Marco Garrido-Cumbrera Consultant for: Honoraria from Novartis as steering committe of this survey, Emilie Desfleurs Employee of: Employee of Novartis Pharma, Francoise Alliot Launois: None declared, LAURENT GRANGE Consultant for: Laurent Grange has received honoraria from Amgen, Lilly and UCB and research support from Lilly, Amgen, UCB, Expanscience, Mylan, Roche diagnostics and TEVA